IP Chemo Shows Survival Benefit

Two studies recently released show a survival benefit for intraperitoneal IP chemotherapy

  • Women with the BRCA1 mutation given IP chemotherapy survived three years longer than those given IV chemotherapy. Read an article about the study here.
  • A study presented at the SGO Annual Meeting showed an improvement in median survival of 10 months. The abstracts can be found on p.56 here.